News & Events

of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in

Entry into a Material Definitive Agreement. On April 13, 2026, Avanos Medical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”). Upon the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the “Mer…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 6, 2026, the Board of Directors of Avanos Medical, Inc. (the “Company”) increased the target value of the annual long-term incentive grant to which David C. Pacitti, the Company’s Chief Executive Officer, is eligible under the Company’s 2021 Long Term Incentive Plan, as amended, from $5,000,000 to $5,500,000, effective beginning in 2026.

Entry into a Material Definitive Agreement. On February 25, 2026, Avanos Medical, Inc. (the “Company”), entered into a letter agreement (the “Agreement”) with Bradley L. Radoff and The Radoff Family Foundation (collectively, the “Radoff Parties”). In connection with the Agreement, the Company’s Board of Directors (the “Board”) has agreed, among other things, to take all actions necessary to: (i) nominate James L. Cunniff to stand for election to the Board at the Company’s 2026 annual meeting…

Results of Operation and Financial Condition On February 24, 2026, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 21, 2025, Avanos Medical, Inc. (the “Company”) eliminated the positions of Chief Commercial Officer and General Counsel, effective December 1, 2025, in connection with a broader organizational restructuring of the Company. The Company notified Kerr Holbrook, the Company’s Senior Vice President and Chief Commercial Officer, and Mojirade Ja…